S&P Global set a €74.40 ($86.51) price objective on STADA Arzneimittel Aktiengesellschaft (ETR:SAZ) in a report published on Friday. The brokerage currently has a sell rating on the stock.

A number of other research analysts have also commented on the company. Independent Research GmbH set a €82.00 ($95.35) price target on STADA Arzneimittel Aktiengesellschaft and gave the company a neutral rating in a research report on Friday. Warburg Research set a €74.40 ($86.51) price target on STADA Arzneimittel Aktiengesellschaft and gave the company a sell rating in a research report on Friday. Nord/LB set a €65.53 ($76.20) price target on STADA Arzneimittel Aktiengesellschaft and gave the company a sell rating in a research report on Thursday, August 31st. Finally, Commerzbank Ag set a €66.25 ($77.03) price target on STADA Arzneimittel Aktiengesellschaft and gave the company a sell rating in a research report on Tuesday, August 22nd. Four equities research analysts have rated the stock with a sell rating and two have assigned a hold rating to the company’s stock. STADA Arzneimittel Aktiengesellschaft presently has a consensus rating of Sell and a consensus price target of €71.43 ($83.06).

STADA Arzneimittel Aktiengesellschaft (ETR:SAZ) opened at €81.50 ($94.77) on Friday. STADA Arzneimittel Aktiengesellschaft has a 52-week low of €41.41 ($48.15) and a 52-week high of €84.20 ($97.91).

ILLEGAL ACTIVITY WARNING: “STADA Arzneimittel Aktiengesellschaft (SAZ) PT Set at €74.40 by S&P Global” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.watchlistnews.com/stada-arzneimittel-aktiengesellschaft-saz-pt-set-at-74-40-by-sp-global/1701503.html.

About STADA Arzneimittel Aktiengesellschaft

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Analyst Recommendations for STADA Arzneimittel Aktiengesellschaft (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel Aktiengesellschaft and related companies with Analyst Ratings Network's FREE daily email newsletter.